MedPath

Effect of montelukast on levels of metalloproteinase-9 (MMP-9), MMP-12, tissue inhibitor metalloproteinase-1 (TIMP-1), procollagen peptide type 1 C-terminal (PICP) and TGF-beta1 on induced sputum of children suffering from intermittent asthma. - ND

Conditions
Intermittent asthma
MedDRA version: 9.1Level: LLTClassification code 10003553Term: Asthma
Registration Number
EUCTR2008-006373-33-IT
Lead Sponsor
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Atopic children (6-14 years) with mild intermittent asthma
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Assumption of ICS in previous 3 months; acute exacerbations of bronchial asthma; pulmonar diseases other than asthma, high- or low-respiratory tract infection in previous 3 weeks.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath